A chemical preformulation study of a host–guest complex of cucurbit[7]uril and a multinuclear platinum agent for enhanced anticancer drug delivery by Kennedy, Alan R. et al.
PAPER www.rsc.org/dalton | Dalton Transactions
A chemical preformulation study of a host–guest complex of cucurbit[7]uril
and a multinuclear platinum agent for enhanced anticancer drug delivery†
Alan R. Kennedy,a Alastair J. Florence,b Fiona J. McInnesb and Nial J. Wheate*b
Received 21st April 2009, Accepted 7th July 2009
First published as an Advance Article on the web 28th July 2009
DOI: 10.1039/b907917c
Single crystal and powder X-ray diffraction have been used to examine the host–guest complex of
cucurbit[7]uril (CB[7]) and the model dinuclear platinum anticancer complex
trans-[{PtCl(NH3)2}2m-dpzm]2+ (di-Pt, dpzm= 4,4¢-dipyrazolylmethane). The single crystal structure
shows that the host–guest complex forms with the di-Pt dpzm ligand within the CB[7] cavity and with
the platinum groups just beyond the macrocycle portals. Binding is stabilised through hydrophobic
interactions and six hydrogen bonds between the platinum ammine ligands and the dpzm pyrazole
amine to the CB[7] carbonyls. Each host–guest complex crystallises with two chloride counterions and
5.5 water molecules. The unit cell comprises four asymmetric units, each of which contains three
crystallographically independent CB[7]–di-Pt moieties. X-Ray powder diffraction demonstrated
structural consistency of the bulk crystals with a single polycrystalline phase that is identical with the
single crystal structure. Finally, the effect of CB[7] encapsulation of the thermal stability of di-Pt was
examined by thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). From the
TGA experiments it was found that free CB[7] and the CB[7]–di-Pt complex lose 11 and 3.5% of their
mass respectively, through the loss of water molecules, upon heating to 160 ◦C. The DSC results showed
that the free dpzm ligand melts between 186 and 199 ◦C, with a standard enthalpy of fusion of
27.92 kJ mol-1. As a 2+ inorganic salt the metal complex does not melt but undergoes several
decomposition events between 140 and 290 ◦C. Encapsulation by CB[7] completely stabilises di-Pt with
no decomposition of either the macrocycle or metal complex at temperatures up to 290 ◦C.
Introduction
Cucurbit[n]urils (CB[n], n = 5, 6, 7, 8, or 10) are a family of
macrocycles made from the acid catalysed reaction of glycoluril
and formaldehyde (Fig. 1).1 Each CB[n] has a hydrophobic cavity
within which small molecules can be encapsulated. The resultant
host–guest complexes are stabilised by hydrophobic effects be-
tween the cavity of the CB[n] and the guest, and can be further
stabilised by ion–dipole or dipole–dipole interactions between the
CB[n] carbonyl portals and the guest.1 Their rigid structure, ease
of synthesis and variety of CB[n] size and functionality mean they
can be used for a variety of applications.2
Multinuclear platinum complexes represent a new class of
anticancer agent that are able to overcomemany forms of cisplatin
resistance in in vitro and in vivo models.3–6 Whilst these complexes
are signiﬁcantly more active than cisplatin, the standard in
platinum-based chemotherapy, they are also considerably more
toxic.5,7,8 BBR3464 is a trinuclear platinum complex that was
recently in Phase II clinical trials,9,10 but has shown little efﬁcacy
in humans because of rapid degradation and deactivation.5 Newer
drugs, like the dinuclear complex CT-3610, are also just as
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Fig. 1 The chemical structures of cucurbit[7]uril (CB[7]) and the model
dinuclear platinum anticancer complex: trans-[{PtCl(NH3)2}2m-dpzm]2+
(di-Pt).
susceptible to degradation, thus driving the need to develop
delivery vehicles for this important class of drugs.
Therefore our group, and other investigators, are particularly
interested in the medicinal application of CB[n]s as both drug
delivery vehicles and in diagnostics/imaging.11–26 Previously we
have reported the use of CB[6], CB[7] and CB[8] as drug delivery
vehicles for platinum-based anticancer agents and have proposed
three-dimensional host–guest complexes based on molecular
modelling.27–34 In the human body, platinum drugs are easily
deactivated and/or degraded by thiol containing proteins andpep-
tides, particularly glutathione.35 Encapsulation of mononuclear
platinum drugs, like cisplatin and oxaliplatin, and multinuclear
platinum drugs like BBR3464 and CT-3610 inside CB[n]s have the
potential to protect these drugs from degradation, which can led
to an increase in the maximum tolerated dose of the drug and/or
an ability to overcome in vivo cisplatin resistance.28
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Previously we have examined the cytotoxicity and DNA
binding of a dinuclear platinum anticancer complex:
trans-[{PtCl(NH3)2}2m-dpzm]2+ (di-Pt) where dpzm = 4,4¢-
dipyrazolylmethane (Fig. 1).36,37 The metal complex is moderately
active in the L1210 and L1210/DDP cell lines36 and is thus a good
model for studying cucurbituril-multinuclear platinum complex
interactions for drugs like BBR3464 and CT-3601. Using 1H
and 195Pt NMR and molecular modelling we have previously
studied the physical chemistry of the host–guest complexes of
di-Pt with CB[7] and CB[8] and the effect of the CB[n]s on the
metal complex’s rate of DNA binding and on its cytotoxicity.29,31
In that work we proposed a three-dimensional structure of the
host–guest complexes based on molecular modelling.
The development of a new drug into a usable pharmaceutical
is dependent not just on in vivo safety and efﬁcacy but also
on the ability to mass produce it in a consistent form with a
known structure and composition. The thermal stability of the
compound is also important as unstable compounds can greatly
add to their cost of production and signiﬁcantly affect their shelf-
life and safety. Therefore, the ability to synthesise stable and
structurally consistent CB[n]-platinum drug host–guest complexes
is very important.
In this paper we examine the host–guest complex of CB[7]
and di-Pt by single crystal and powder X-ray diffraction. The
ability of CB[7] to thermally stabilise di-Pt was also examined
using thermogravimetric analyses (TGA) and differential scanning
calorimetry (DSC). The results of theX-ray structural analysis and
DSC/TGA are discussed in the context of drug production and
pharmaceutical preformulation.
Experimental
Crystal growth
The metal complex di-Pt36 and CB[7]38 were dissolved in ~100 mL
of water with heating and sonication and left to evaporate slowly
over a period of 2–3 weeks to yield colourless, square-shaped
crystals.
Single crystal X-ray structure†
Structure solution and reﬁnement used programs from the
SHELX family.39 Data were measured at station 9.8 of the
Daresbury synchrotron radiation source to give;monoclinic, space
group P2/c, a = 28.225(8), b = 22.859(7), c = 29.728(9) A˚,
b = 98.209(4)◦, V = 18984(10) A˚3, Z = 10, l = 0.69460 A˚,
m = 3.666 mm-1, T = 120 K; 139661 reﬂections, 33459 unique,
Rint 0.0665; ﬁnal reﬁnement to convergence on F 2 and with 2651
reﬁned parameters gave R = 0.0651 (F , 24264 obs. data only) and
Rw = 0.2001 (F 2, all data), GOF = 1.108. Data were treated with
the SQUEEZEoption in PLATONto remove a total of 51 residual
electrons (presumed to be partial water) from a total 812 A˚3 of void
space.40
X-Ray powder diffraction
A sample was lightly ground in an agate mortar and pestle and
ﬁlled into a 0.7 mm borosilicate glass capillary. The sample was
mounted and aligned on a Bruker-AXS D8 Advance diffractome-
ter (Table 1) and data were collected at room temperature in the
Table 1 Single crystal X-ray diffraction data for the host–guest complex
of CB[7] and di-Pt
Crystal data Value
Empirical formula C49H71.06Cl4N36O19.53Pt2
Formula weight 2010.96 g mol-1
Crystal system Monoclinic
Space group P2/c
Unit cell dimensions
a/A˚ 28.225(8)
b/A˚ 22.859(7)
c/A˚ 29.728(9)
a/◦ 90.00
b/◦ 98.209(4)
g /◦ 90.00
Volume/A˚3 18984(10)
Density (calculated)/Mg m-3 1.757
Crystal size/mm 0.04 ¥ 0.04 ¥ 0.02
range 3–40◦ 2q (2 kW; Cu Ka1, l = 1.54056 A˚; step size 0.017◦
2q, step time= 2 s). The data from the polycrystalline sample were
compared to the single-crystal structure via a Pawley41 reﬁnement
as implemented in TOPAS Academic v4.1.42
Thermogravimetric analysis and differential scanning calorimetry
Experiments were conducted using aMettler Toledo TGA/SDTA
851e and a Mettler Toledo DSC 8222e, respectively. Each sample
(approximately 5–10 mg) was placed in an alumina or sealed
aluminiumpan, andweighed. Sampleswere then heated at a rate of
10 ◦C min-1. Experiments were performed on multiple, individual
batches to conﬁrm product consistency.
Results and discussion
Single crystal X-ray structure
The single crystal X-ray structure shows that CB[7] and di-Pt form
a 1:1 host–guest complex where the metal complex is partially
encapsulated within the macrocycle (Table 1 and Fig. 2). The
dpzm ligand is located completely within the CB[7] cavity where
Fig. 2 The single crystal X-ray diffraction structure of the host–guest
complex of CB[7] and di-Pt.
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binding is stabilised by hydrophobic forces and two hydrogen
bonds (1.98 A˚) between both pyrazole amine groups to one
CB[7] carbonyl oxygen at each portal. The platinum ammine
ligands are located just beyond the CB[7] portals and help to
further stabilise the host–guest complex through an additional
four hydrogen bonds (2.4 A˚) to the CB[7]-carbonyls (Fig. 3). As
well as the two chloride counterions of di-Pt, each host–guest
complex crystalliseswith 5.5watermolecules.Whilst thewaters are
bordering on disordered within the structure some form hydrogen
bonds with the carbonyl portals of CB[7] and the ammine groups
of di-Pt. The unit cell consists of four asymmetric units, each of
which contains three crystallographically independent CB[7]–di-
Ptmoieties and the associated counterions andwaters of hydration
(Fig. 4). This is consistent with the X-ray structures of other CB[7]
complexes.43
Fig. 3 Hydrogen bonding between di-Pt and CB[7]. Six such hydrogen
bonds stabilise the host–guest complex; three at each CB[7] portal.
The single crystal X-ray diffraction structure is in good
agreement with our previously proposed molecular model31 and
validates the modelling technique for the study of further drugs
with CB[n]s where suitable single crystals for analysis cannot
be obtained. In the molecular model the Pt–Pt distance was
calculated to be 10.05 A˚, which is shorter than the crystal
determined length of 10.49 A˚. In the model the angle of the
methylene bonds to the pyrazoles is 114.9◦, but is 113.7◦ in the
crystal, and ﬁnally, in the molecular model both platinum atoms
maintain a perfect square-planar shape with bond angles of 90
(±0.1)◦. In the crystal structure, the platinum atoms form a slightly
distorted square-planar shape with the bond angles between 88.4
and 91.4◦.
The only large difference between the model and the crystal
structure is seen in the structure of the CB[7] molecule. The portals
of CB[7] are normally symmetrical with a van der Waals radius
of 5.4 A˚ and this symmetry is observed in the molecular model of
CB[7] and di-Pt;31 however, from the single X-ray crystal structure
the binding of di-Pt distorts the CB[7] into an ellipsoid shape, with
one long van derWaals axis of~5.9 A˚ and one shorter axis of 4.8 A˚.
This structural change appears to be due to the hydrogen bonding
between the platinum ammine ligands and the CB[7] carbonyl
groups. The height of the CB[7] in both the model and the X-ray
structure remains unchanged at 9.1 A˚.
Fig. 4 The single crystal X-ray diffraction unit cell of the host–guest
complex ofCB[7] anddi-Pt. Eachunit cell consists of four asymmetric units
made of one CB[7], one di-Pt, two chloride counterions and 5.5 water
molecules.
X-Ray powder diffraction
A Pawley-type ﬁt to the data, in which background, zero-point,
peak shape and unit cell parameters describing the proﬁle were
reﬁned, yielded an excellent ﬁt to the data with no signiﬁcant
diffraction features unaccounted for (Rwp = 0.016; reﬁned unit
cell parameters a= 28.225(8) A˚, b= 22.859(7) A˚, c= 29.728(9) A˚,
b angle = 98.209(4)◦; Fig. 5). These values are consistent with
slight thermal expansion of the unit cell compared to the single
crystal values as a result of the higher temperature of XRPD
data collection (XRPD, 273 K; single crystal diffraction data,
120 K). The comparison conﬁrms that the polycrystalline sample
is consistent with the single crystal structure.
The production of structurally consistent formulations of host–
guest complexes of CB[n]s and platinum drugs, in terms of both
the host–guest complex formed but also the crystal packing and
hydration, is required for newdrugs to be developed successfully as
pharmaceuticals. Given that single crystal samples may not always
be representative of bulkmaterial, theXRPDanalysis ofCB[7]–di-
Pt polycrystalline sample is important to conﬁrm bulk phase iden-
tity. This is particularly true when dealing with crystals of CB[n]s
and their host–guest complexes, as typically all CB[n]s crystallize
with a large number of water molecules. As discussed earlier CB[7]
and di-Pt crystallised with only 5.5 water molecules, but other
types of host–guest complexes of CB[7] and platinum complexes,
like cisplatin, oxaliplatin and platinum-based DNA intercalators
have been shown to contain between 3 and 13 water molecules per
CB[n]-platinum complex in their structures.30,43,44 These different
hydrate forms can lead to signiﬁcant changes in crystal packing of
This journal is © The Royal Society of Chemistry 2009 Dalton Trans., 2009, 7695–7700 | 7697
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Fig. 5 Final observed (points), calculated (line) and difference [(yobs - ycalc)] proﬁles for the Pawley reﬁnement to the XRPD pattern of the polycrystalline
CB[7]–di-Pt sample. Inset: low-angle region of the pattern highlighting excellent correspondence between observed and calculated proﬁles.
CB[n]s in different samples. Recent studies examining the synthesis
of CB[6] in hydrochloric acid using microwave irradiation pro-
duced two different CB[6] crystal morphologies. We believe these
two morphologies represent CB[6] crystals with differing numbers
of water molecules in the their unit cells, and thus a different CB[6]
w/w composition.When designing a pharmaceutical preparation,
it is often critical to separate different crystal types to ensure a
consistent amount of drug is delivered. The single polycrystalline
phase observed for the bulk crystals ofCB[7]–di-Pt is promising for
the future application of CB[n]s as drug delivery vehicles for mult-
inuclear platinum drugs, as it indicates that these host–guest com-
plexes can be synthesised with high chemical and physical purity.
Thermal gravimetric analysis
In addition to the problems of consistent synthesis of crystalline
forms, the large number of water molecules in CB[n] host–guest
complexes, including CB[7]–di-Pt, may be problematic in trying to
obtain stable pharmaceutical formulations. Loss of one or more
water molecules from a CB[n]–drug complex could have effects
on any component of the formulation, including: a change from
one crystalline form to another, a change from amorphous to
crystalline material and vice versa, or drug degradation. Such
changes in the physical form can also affect ﬂowability during
automated powder processing, compaction properties of oral
formulations, and drug dissolution proﬁle/bioavailability (e.g. if
administered in a tablet or non-IV dosage form).
Using CB[6] with differing numbers of hydration water
molecules, Germain et al. examined the dehydration of CB[6]
by TGA.45 Water loss from solids of CB[6] is an endothermic
process that occurs between 50 and 200 ◦C. Similarly, loss of
water is seen from the solid powder forms of free CB[7] and the
CB[7]–di-Pt complex in their respective TGA spectra (Fig. 6).
Water loss begins at 40 ◦C and is complete in one step by
Fig. 6 The thermogravimetric trace of (red) free CB[7] and (black)
the CB[7]–di-Pt host–guest complex, showing the loss of mass with
temperature.
~110 ◦C. Free CB[7] loses 11% of its mass over this temperature
range, corresponding to the dehydration of approximately seven
water molecules, which is consistent with the average hydration
state of CB[7].38 The CB[7]–di-Pt complex loses 3.4% of its mass
in the same temperature range, which corresponds to the loss of 4
of the 5.5watermolecules.No further loss of water is seen at higher
temperatures. An analysis of further individual batches yields
similar traces indicating production of material with a consistent
hydration state.
These TGA results therefore highlight a problem in developing
pharmaceutical preparations of CB[n]s with platinum drugs. In
order to prevent water loss, a method of drying these host–guest
complexes to remove as much water as possible, but without
degrading the drug before they are formulated, may need to be
developed.
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Differential scanning calorimetry
As well as providing protection to platinum drugs from degrada-
tion inside cancer cells, CB[n]s may also act to thermally stabilise
drugs from degradation during manufacture and storage. Some
platinum drugs, particularly oxaliplatin, are unstable and degrade
easily in the solid state or in aqueous solutions.43 Previously, CB[7]
binding has been shown to reduce qualitatively the degradation
rate of oxaliplatin, and it was of interest to see if a similar effect
acts for multinuclear drugs.43
As such, the melting and thermal degradation of free dpzm,
di-Pt, CB[7] and the CB[7]–di-Pt was examined by DSC. The
spectrum of free dpzm is consistent with other small, unchanged
organic molecules (Fig. 7); the compound begins to melt at
186.5 ◦C and is complete at 198.8 ◦C. From this spectrum a
standard enthalpy of fusion of 27.92 kJ mol-1 can be calculated
for free dpzm. The di-Pt metal complex as a 2+ inorganic salt does
not melt at temperatures below 300 ◦C. As such, the peaks seen in
the DSC spectrum of free di-Pt at temperatures around 190 and
245 ◦C represent two degradation events of the metal complex.
Further degradation is seen at temperatures beyond 270 ◦C. In
the DSC spectra of free CB[7] and the CB[7]–di-Pt host–guest
complex the only peaks of interest occur between 40 and 130 ◦C,
which represent the loss of water from the system (consistent with
the TGA results). No degradation is observed at temperatures
up to 290 ◦C. Overall, the results indicate that CB[7] provides
signiﬁcant thermal stability to di-Pt, which may allow the heating
of platinum drugs to temperatures of around 100 ◦C for prolonged
periods to remove the water from the solid formulations of CB[n]s
and platinumdrugs, thus providing amore stable and reproducible
drug product.
Fig. 7 The differential scanning calorimetry traces of (blue) di-Pt, (red)
dpzm, (green) CB[7], and (black) the CB[7]–di-Pt host–guest complex.
Conclusions
In this paper we examined the host–guest complex of the macro-
cycle CB[7] with the model dinuclear platinum complex di-Pt. A
1:1 host–guest complex is formed where the platinum complex is
partially encapsulated by CB[7] with the dpzm ligand of the metal
complex inside themacrocycle cavity andwith the platinumgroups
sitting just beyond the portals. Binding is stabilised byhydrophobic
effects and six hydrogen bonds. The bulks crystals of CB[7] and
di-Pt also produce a single polycrystalline phase, possibly making
the resultant complex easier to process and formulate, than if
different crystal structures (e.g. hydrates) were produced; as is
sometimes the case with CB[n]s. Both free CB[7] and the CB[7]–di-
Pt host–guest complex contain signiﬁcant amounts ofwaterwithin
their structures, which may make the synthesis of stable CB[n]-
platinum drug formulations difﬁcult. DSC demonstrated that at
temperatures up to 290 ◦C, CB[7] completely protected di-Pt from
thermal degradation. This resultmay indicate that CB[n]-platinum
drug complexes may be heated for prolonged time periods in order
to removewater from their structures before their formulation into
usable dosage forms.
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